Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Sales (2018 - 2024)

Denali Therapeutics has reported Return on Sales over the past 7 years, most recently at 3.31% for Q2 2024.

  • Quarterly Return on Sales fell 332.0% to 3.31% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 3.31% through Jun 2024, down 331.0% year-over-year, with the annual reading at 0.0% for FY2023, 3.0% up from the prior year.
  • Return on Sales was 3.31% for Q2 2024 at Denali Therapeutics, down from 0.0% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.01% in Q4 2020 and troughed at 700.41% in Q1 2021.
  • The 5-year median for Return on Sales is 0.06% (2020), against an average of 40.1%.
  • Year-over-year, Return on Sales plummeted -70025bps in 2021 and then skyrocketed 70039bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 0.01% in 2020, then plummeted by -878bps to 0.06% in 2021, then plummeted by -64bps to 0.1% in 2022, then soared by 96bps to 0.0% in 2023, then plummeted by -75286bps to 3.31% in 2024.
  • Per Business Quant, the three most recent readings for DNLI's Return on Sales are 3.31% (Q2 2024), 0.0% (Q1 2024), and 0.0% (Q4 2023).